Ryan Vathy
ryanvpharmd.bsky.social
Ryan Vathy
@ryanvpharmd.bsky.social
ID PharmD 🦠🧫
Ole Miss Alumn
Reposted by Ryan Vathy
@ryanvpharmd.bsky.social @brainofbpharm.bsky.social: This study evaluated the impact of a guidance document on treatment decisions, clinical outcomes for CRAB, Steno. Our results demonstrate that implementing a treatment guideline may ⬆️ guideline directed treatment. doi.org/10.1017/ash....
Impact of institutional treatment guidance on the management and outcomes of Stenotrophomonas maltophilia and carbapenem-resistant Acinetobacter baumannii infections | Antimicrobial Stewardship & Healthcare Epidemiology | Cambridge Core
Impact of institutional treatment guidance on the management and outcomes of Stenotrophomonas maltophilia and carbapenem-resistant Acinetobacter baumannii infections - Volume 5 Issue 1
doi.org
December 11, 2025 at 8:00 PM
Reposted by Ryan Vathy
VUMC 🏥 is recruiting for a PGY2 ID Pharmacy resident 🧫🦠 next year! If you or someone you know is interested, come check out one of our virtual open house sessions.

We have an amazing team of 4 inpatient, 2 OPAT, 1 peds, and 1 HIV pharmacists (and more) to work with!
November 5, 2025 at 9:49 PM
Reposted by Ryan Vathy
‼️Just shared at #IDWeek2025 & now published in @ofidjournal.bsky.social cephalexin vs. cefdinir for tx of uUTI in females. Spoiler: Cefdinir was independently associated with/failure & cefdinir pts were twice as likely to fail. Let’s stop Rx’ing cefdinir for UTI! 🛑💊 academic.oup.com/ofid/article...
Cefdinir Versus Cephalexin for the Treatment of Uncomplicated Urinary Tract Infections
Due to its poor bioavailability and urinary excretion, cefdinir may be a suboptimal agent for UTI treatment. Our findings demonstrate that patients treated
academic.oup.com
October 24, 2025 at 12:01 AM
Reposted by Ryan Vathy
Finally published
🆕🔥DOTS RCT
Among participants with complicated S aureus bacteremia who achieved blood culture clearance, dalbavancin was not superior to standard therapy for achieving a more desirable outcome at day 70 #idsky
jamanetwork.com/journals/jam...
August 13, 2025 at 3:07 PM
Reposted by Ryan Vathy
What’s the optimal cefazolin dose for MSSA CNS infections?
New PK/PD data says: it’s not just about higher doses—MIC matters.
2g q6h works only if MIC <=0.5 mg/L
For MIC:1-2 mg/L, continuous infusion (10–12g/day) may be needed to hit PD targets #idsky
journals.asm.org/doi/10.1128/...
May 20, 2025 at 4:19 PM
Reposted by Ryan Vathy
The SNAP trial may finally resolve some of the longest-running debates in SAB management (cefazolin vs semi-synthetic PCN? Is PCN really active vs PSSA?).
Huge congrats to Drs. Joshua Davis, Steven Tong, & the global team who made this ambitious trial happen. #IDSky blogs.jwatch.org/hiv-id-obser...
SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia
For those who do hospital-based patient care, the significance of Staphylococcus aureus bacteremia (SAB) cannot be overstated. It’s one of the most frequent reasons for infectious disease consultation...
blogs.jwatch.org
April 18, 2025 at 8:35 PM
Reposted by Ryan Vathy
The entire archive of CDC datasets can be found here.

HUGE shoutout to data archivists- this work is important 👏🙌🏻

archive.org/details/2025...
February 1, 2025 at 6:33 PM
Reposted by Ryan Vathy
📋👀 Did you miss any of these articles from 2024?

📲 www.idstewardship.com/year-review-...

#IDsky with @absteward.bsky.social
December 14, 2024 at 10:40 PM